Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates

Gene Therapy

Volumn 19, Issue 10, 2012, Pages 999-1009

  Lai, C M ^a   Estcourt, M J ^a   Himbeck, R P ^a   Lee, S Y ^b   Yew San Yeo, I ^b   Luu, C ^c   Loh, B K ^b   Lee, M W ^b   Barathi, A ^c   Villano, J ^d   Ang, C L ^b   Van Der Most, R G ^e   Constable, I J ^a   Dismuke, D ^f   Samulski, R J ^g   Degli Esposti, M A ^a   Rakoczy, E P ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^c SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Immunology; Neovascularization; Retinal diseases

Indexed keywords

GENE THERAPY AGENT; PARVOVIRUS VECTOR; RECOMBINANT RECEPTOR; VASCULOTROPIN RECEPTOR 1;

A WAVE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; B WAVE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DISTRIBUTION; ELECTRORETINOGRAPHY; EYE EXAMINATION; EYE FUNDUS; IMMUNOASSAY; INJECTION; MACACA FASCICULARIS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RISK ASSESSMENT; SUBRETINAL FLUID; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VITREOUS BODY;

ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; MACACA FASCICULARIS; RETINA; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

ADENO-ASSOCIATED VIRUS; ANIMALIA; PRIMATES;

EID: 84867403190     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.169     Document Type: Article

References (61)

1. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in thevitreous ofeyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450. (Pubitemid 24307211)
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487. (Pubitemid 24356306)
3. Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD etal. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009; 116: 2158-2164.
4. Lai CM, Dunlop SA, May LA, Gorbatov M, Brankov M, Shen WY et al. Generation of transgenic mice with mild and severe retinal neovascularization. Br J Ophthalmol 2005; 89: 911 -916. (Pubitemid 40904820)
5. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Therapy 2002; 9: 804-813. (Pubitemid 34679308)
6. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W et al. Transgenic mice with increased expression ofvascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997; 151: 281 -291.
7. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release ofVEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997; 64: 505-517. (Pubitemid 27321334)
8. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
9. Bainbridge JW, Mistry A, De Alwis M, Paleolog E, Baker A, Thrasher AJ et al. Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Therapy 2002; 9: 320-326. (Pubitemid 34285145)
10. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-346. (Pubitemid 34250056)
11. Lai CM, Shen WY, Brankov M, Lai YK, Barnett NL, Lee SY et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 2005; 12: 659-668. (Pubitemid 41350147)
12. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 614-625. (Pubitemid 46625484)
13. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
14. Zhou B, Wang B. Pegaptanib for the treatment of age-related macular degeneration. Exp Eye Res 2006; 83: 615-619. (Pubitemid 44183805)
15. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65 e5.
16. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-248.
17. Schmidt-Erfurth U, Eldem B, Guymer R, KorobelnikJF, Schlingemann RO, Axer-Siegel R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration The EXCITE Study. Ophthalmology 2010; 118: 831-839.
18. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS et al. Incidence of endophthalmitis related to intravitreal injection ofbevacizumab and ranibizumab. Retina 2008; 28: 1395-1399.
19. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007; 27: 523-534. (Pubitemid 46905141)
20. Lai CM, Estcourt MJ, Wikstrom M, Himbeck RP, Barnett NL, Brankov M et al. rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci 2009; 50: 4279-4287.
21. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
22. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328. (Pubitemid 26331903)
23. Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H. Experimental subretinal neovascularization is inhibited by adenovirus-mediated solubleVEGF/flt-1 receptor gene transfection: a role ofVEGF and possible treatment for SRN in age-related macular degeneration. Gene Therapy 2000; 7: 978-985. (Pubitemid 30386663)
24. Igarashi T, Miyake K, Masuda I, Takahashi H, Shimada T. Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 2010; 21: 631 -637.
25. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 2003; 14: 129-141. (Pubitemid 36422598)
26. Rota R, Riccioni T, Zaccarini M, Lamartina S, Gallo AD, Fusco A et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 2004; 6: 992 -1002. (Pubitemid 40228114)
27. Ideno J, Mizukami H, Kakehashi A, Saito Y, Okada T, Urabe M et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. IntJMolMed2007; 19: 75-79.
28. Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12: 1299-1310. (Pubitemid 32681844)
29. FlotteTR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ etal. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004; 15: 93-128. (Pubitemid 38147192)
30. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509-521. (Pubitemid 38223630)
31. Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E et al. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis 2009; 68: 1247-1254.
32. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105. (Pubitemid 46935946)
33. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577-588. (Pubitemid 43827251)
34. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972. (Pubitemid 36857981)
35. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13: 419-422. (Pubitemid 46559826)
36. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P et al. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther2004; 15: 1131 -1154. (Pubitemid 39552294)
37. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231 -2239. (Pubitemid 351724452)
38. Hauswirth W, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L et al. Phase I trial of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results. Hum Gene Ther 2008; 19: 979-990.
39. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J et al. Safety and efficacy of genetransferfor Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248. (Pubitemid 351724453)
40. Frank KM, Hogarth DK, Miller JL, Mandal S, Mease PJ, Samulski RJ et al. Investigation of the causeofdeath in a gene-therapy trial. N Engl J Med 2009; 361: 161-169.
41. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347. (Pubitemid 43355084)
42. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28: 710-722.
43. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715. (Pubitemid 14035254)
44. Chakrabarti LA, Lewin SR, Zhang L, Gettie A, Luckay A, Martin LN et al. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol 2000; 74: 1209-1223. (Pubitemid 30044070)
45. Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC et al. Development and homeostasis of Tcell memory in rhesus macaque. J Immunol 2002; 168: 29-43. (Pubitemid 34014099)
46. Johnson CJ, Berglin L, Chrenek MA, Redmond TM, Boatright JH, Nickerson JM. Technical brief: subretinal injection and electroporation into adult mouse eyes. Mol Vis 2008; 14: 2211 -2226.
47. Jacobson SG, Boye SL, Aleman TS, Conlon TJ, Zeiss CJ, Roman AJ et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 2006; 17: 845-858. (Pubitemid 44681454)
48. Provost N, Le Meur G, Weber M, Mendes-Madeira A, Podevin G, Cherel Y et al. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther 2005; 11: 275-283.
49. Dudus L, Anand V, Acland GM, Chen SJ, Wilson JM, Fisher KJ et al. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res 1999; 39: 2545-2553. (Pubitemid 29197300)
50. Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther 2011; 19: 326-334.
51. Graubert MD, Ortega MA, Kessel B, Mortola JF, Iruela-Arispe ML. Vascular repair after menstruation involves regulation of vascular endothelial growth factor-receptor phosphorylation by sFLT-1. Am J Pathol 2001; 158: 1399 -1410. (Pubitemid 32281304)
52. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001; 4: 143-154. (Pubitemid 34032700)
53. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB et al. Preeclampsia and future cardiovascular disease: potential role ofaltered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004; 89: 6239-6243. (Pubitemid 39628439)
54. Chung NA, Lydakis C, Belgore F, Blann AD, Lip GY. Angiogenesis in myocardial infarction. An acute or chronic process? Eur HeartJ 2002; 23: 1604-1608. (Pubitemid 35221565)
55. Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 2011; 19: 260-265.
56. Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Therapy2009; 16: 10-16.
57. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997; 91: 695 - 704. (Pubitemid 27513660)
58. Hoffman LM, Maguire AM, Bennett J. Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Invest Ophthalmol Vis Sci 1997; 38: 2224-2233. (Pubitemid 27446939)
59. Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008; 14: 1760-1769.
60. Li W, Kong F, Li X, Dai X, Liu X, Zheng Q et al. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye. Mol Vis 2009; 15: 267-275.
61. Shen WY, Garrett KL, Wang CG, Zhang K, Ma ZZ, Constable IJ et al. Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey. Lab Invest 2002; 82: 167-182. (Pubitemid 34160454)